Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Apparently the drunk raccoon I mentioned a few weeks ago is a repeat offender. Onto the biotech news today. STAT+ Exclusive Story Already have an account? Log in This article is exclusive…
This essay is part of a First Opinion series on the future of the National Institutes of Health and American science. Around the world, nations with robust research and development infrastructure race to create therapeutics that meet the needs of their residents. Simply put, they dictate research priorities based on need. During the Covid pandemic,…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss the implications of a child’s tragic death after receiving a brain-focused gene therapy, hear Siddhartha Mukherjee opine on why the next frontier in cancer treatment is metabolic, and more. The need-to-know…
A new kind of oral antibiotic to treat gonorrhea has secured Food and Drug Administration approval, the second time in two days that a new drug for the common sexually transmitted infection has come through licensure. Neisseria gonorrhoeae, the bacterium that causes gonorrhea, has for decades been evolving to evade the antibiotics used to treat…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I hope my fellow Midwesterners stay warm this weekend. Let’s get into the news today. A new FDA drug regulator will face a distrustful staff On Monday, Tracy Beth Høeg will become acting director…
WASHINGTON — In 2008, Tracy Beth Høeg, then a resident physician and ultramarathon runner, expressed dismay at vice presidential candidate Sarah Palin’s denial of climate change. “To stare such abundant scientific evidence in the face and make the blanket statement that you don’t believe it,” Høeg wrote in her blog. “What will the future of…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. The obesity data keeps coming this week. We’ll get straight into it. The need-to-know this morning Rezolute said its experimental drug failed to reduce episodes of low blood sugar in patients with…
WASHINGTON — Congress is poised to pass the Biosecure Act after two years of incremental changes that watered down the bill’s curbs on Chinese biotechs and made the law more palatable for U.S. biopharma companies. The House passed a defense budget bill today that includes Biosecure, which restricts how U.S. pharmaceutical and biotechnology companies do…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we preview a contentious generic drug dispute that may end up at the Supreme Court, discuss how the FDA’s new stance on vaccines could impact RSV shots, and more. ‘Skinny labels’ may…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between government and industry needs modernized rules, and more. Terns drug shows strong early…